Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry.

Details

Serval ID
serval:BIB_6C3B40CEFF11
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry.
Journal
International journal of cardiology
Author(s)
Scognamiglio G., Fusco F., Hankel T.C., Bouma B.J., Greutmann M., Khairy P., Ladouceur M., Dimopoulos K., Niwa K., Broberg C.S., Miranda B., Budts W., Bouchardy J., Schwerzmann M., Lipczyńska M., Tobler D., Tsai S.F., Egbe A.C., Aboulhosn J., Fernandes S.M., Garr B., Rutz T., Mizuno A., Proietti A., Alonso-Gonzalez R., Mulder BJM, Sarubbi B.
Working group(s)
non-vitamin K antagonist oral anticoagulants for thromboembolic prevention in adult congenital heart disease (NOTE) registry Investigators
ISSN
1874-1754 (Electronic)
ISSN-L
0167-5273
Publication state
Published
Issued date
01/01/2021
Peer-reviewed
Oui
Volume
322
Pages
129-134
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Patients with systemic right ventricle (sRV), including transposition of great arteries (TGA) after atrial switch procedure and congenitally corrected transposition of great arteries (ccTGA), may require anticoagulation for thromboembolism (TE) prevention. In the absence of data on non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs) remain the agent of choice. We investigated the safety, efficacy and feasibility of NOACs treatment in adults with sRV in a worldwide study.
This is an international multicentre prospective study, using data from the NOTE registry on adults with sRV taking NOACs between 2014 and 2019. The primary endpoints were TE and major bleeding (MB). The secondary endpoint was minor bleeding.
A total of 76 patients (42.5 ± 10.0 years, 76% male) with sRV (74% TGA, 26% ccTGA) on NOACs were included in the study. During a median follow-up of 2.5 years (IQR1.5-3.9), TE events occurred in 3 patients (4%), while no MB episodes were reported. Minor bleeding occurred in 9 patients (12%). NOAC treatment cessation rate was 1.4% (95%CI:0.3-4%) during the first year of follow-up. All the patients with TE events had a CHA <sub>2</sub> DS <sub>2</sub> -VASc score ≥ 2 and impaired sRV systolic function at baseline. The total incidence of major events during follow-up was significantly lower compared to historical use of VKAs or aspirin before study inclusion (1.4% (95%CI:0.29-4%) vs 6,9% (95%CI:2.5-15.2%); p = .01).
In this prospective study, NOACs appear to be well-tolerated, with excellent efficacy and safety at mid-term in patients with sRV.
Keywords
Anticoagulation, Bleeding, NOACs, Non-vitamin K antagonist oral anticoagulants, Systemic right ventricle, Thromboembolism
Pubmed
Web of science
Create date
28/08/2020 7:48
Last modification date
04/09/2021 5:35
Usage data